

June 2, 2018

**BSE Limited**  
1<sup>st</sup> Floor, P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051

Re.: Press Release.

Dear Sir / Madam,


We enclose herewith a copy of press release dated June 2, 2018 titled “Zydus receives final approval from the USFDA for Doxycycline Hyclate Capsules USP.”

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking You,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**



**UPEN H. SHAH**  
**COMPANY SECRETARY**



Encl.: As above

## **Zydus receives final approval from the USFDA for Doxycycline Hyclate Capsules USP**

*Ahmedabad, 02 June, 2018*

Zydus Cadila has received the final approval from the USFDA to market Doxycycline Hyclate Capsules USP, 50 mg and 100 mg. It is a tetracycline antibiotic used for treatment of a wide variety of bacterial infections, including those that cause acne. This medication is also used for prophylaxis of malaria. It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*